

Outlining Containment Plans for CR-PA

Master Worksheet



Part 1: State Notification

A short-stay acute care hospital clinical laboratory identifies a carbapenem-resistant *Pseudomonas aeruginosa* (CR-PA) from a sputum culture taken on March 1. The isolate is forwarded to the state lab for mechanism testing through the AR Lab Network.

Your state laboratory was able to test and validate that the isolate produces active-on-imipenem Metallo- β -lactamase (IMP), a plasmid-mediated carbapenemase that is extremely rare in the U.S. This is the first IMP-producing CR-PA for the hospital and for the region.

1. Are there additional actions that need to be taken at this point?

2. What additional information do you need?

Outlining Containment Plans for CR-PA

Master Worksheet



Part 2: Case History

1. What are the key pieces of information from the hospital's infection preventionist?

Outlining Containment Plans for CR-PA

Master Worksheet



Part 3: Immediate Recommendations & Next Steps

1. Do you need to notify any facilities about this patient's status?

2. What recommendation(s) do you make to the short-stay ACH to prevent spread of IMP-producing organisms?

Additional question prompts:

- Are there special considerations for the IMP mechanism? For *Pseudomonas* vs CRE?
- Are there recommendations and AR Lab Network resources available to avert a similar situation when patients with recent healthcare exposure outside the U.S. are admitted in the future?

Outlining Containment Plans for CR-PA Master Worksheet

Part 3: Immediate Recommendations & Next Steps

-
-
- 3. What recommendation(s) do you make to the LTACH to prevent spread of IMP-producing organisms?**
- 4. Do you anticipate challenges in implementation of these recommendations at either facility? If so, what are they?**

 - How might these challenges be overcome?**

Outlining Containment Plans for CR-PA

Master Worksheet



Part 4: Facility Assessment

1. Do you recommend screening to assess for IMP transmission in the short-stay ACH?

- If yes, which patients would you recommend prioritizing?
- How would you explain the importance of screening to the facility?
- How would you explain available resources and screening logistics to the facility?

2. Do you recommend screening to assess for IMP transmission at the LTACH?

- If yes, who do you recommend prioritizing for screening?

Outlining Containment Plans for CR-PA

Master Worksheet



Part 5: Transmission Screening & Point Prevalence Surveys

1. Who approves each request for colonization screening?

2. How will you coordinate with the AR Lab Network regional lab for screening?

- What logistical considerations may the regional lab have?

Outlining Containment Plans for CR-PA

Master Worksheet



Part 5: Transmission Screening & Point Prevalence Surveys

3. Who will collect the screening swabs?

- Do you need patient permission to collect screening swabs?
- What documents are available to provide information about screening to patients?

4. Who will receive testing results?

- When will they be available?
- How will they be communicated?

Outlining Containment Plans for CR-PA

Master Worksheet



Part 5: Transmission Screening & Point Prevalence Surveys

5. After you conduct the point prevalence surveys, what are your next steps for the ACH?

- What interventions do you recommend?
- Should additional screening be pursued? If yes, what kinds?

6. After you conduct the point prevalence surveys, what are your next steps for the LTACH?

- What interventions do you recommend?
- Should additional screening be pursued? If yes, what kinds?

Outlining Containment Plans for CR-PA

Master Worksheet



Part 5: Transmission Screening & Point Prevalence Surveys

7. Does understanding regional epidemiology of KPC within your state help you interpret the findings of the PPS?

- Would your response be different if this occurred in your higher incidence region?

8. Can the regional lab determine which organisms harbor the IMP and KPC mechanisms

Outlining Containment Plans for CR-PA

Master Worksheet



Part 5: Transmission Screening & Point Prevalence Surveys

9. How can you evaluate whether infection control practices are improving?

Outlining Containment Plans for CR-PA

Master Worksheet

99 Part 6: Follow-Up

1. Do you recommend additional screening at the ACH after the first point prevalence survey?

2. Do you recommend additional screening at the ACH after the second point prevalence survey?

Outlining Containment Plans for CR-PA

Master Worksheet

99 Part 6: Follow-Up

3. After LTACH Point Prevalence Survey #2, is transmission occurring?

- If yes, what factors might be contributing to transmission?
- What recommendations would you make to the facility?
- If you decide to conduct additional screening, would you screen facility-wide or perform more focused screening?

4. After LTACH Site Visit #2 and Point Prevalence Survey #3, transmission is still occurring on this floor of the facility. What additional measures would you consider?

Outlining Containment Plans for CR-PA

Master Worksheet

99 Part 6: Follow-Up

5. After LTACH Site Visit #3 and Point Prevalence Survey #4, what feedback on infection control practices do you provide to the facility?

- What are your next steps?

6. After LTACH Point Prevalence Survey #5 & #6, transmission has stopped at this facility. Is there anything else to do?